
All records · Back to the record · Dossier (sources.md) · Terminology · Report a problem · Comments
Everything a reviewer needs to judge, gathered from the record. Release status: draft.
| Review | Status | Reviewer | Date | Notes |
|---|---|---|---|---|
| schema validation | not_started | Run scripts/build.ps1 -Conformance. | ||
| clinical review | not_started | Awaiting clinician review; check the diagnosis by EBUS with infection excluded, the decision to complete cardiac MRI and FDG-PET before glucocorticoids, the prednisone dose and taper with methotrexate, the defibrillator decision after an inducible electrophysiology study with an ejection fraction of 47 percent, the handling of calcium and vitamin D with alendronate, atovaquone instead of trimethoprim-sulfamethoxazole with methotrexate, and the touring plan. | ||
| provenance review | not_started | She died in 1972; the recent-death rule does not apply. Claims rest on The New York Times obituary, the presidential statement, PBS, Biography.com, New Orleans Historical, TheWrap and Wikipedia's summary of Goreau's biography. The cause of death and the cardiac sarcoidosis interpretation are R; everything clinical is synthetic. | ||
| safe messaging review | not_started | No mental health or substance claim is made; mood screens are synthetic and below the threshold for a safety assessment. Weight is recorded as measured, without comment on her body. Her death is recorded once, without detail. No relative, spouse, colleague or historical physician is given a role in the modern episode. |
Checks the monitoring protocol called for that the schedule did not perform. Each is recorded with its outcome and corrective action, never filled with an invented result.
| Visit | Measure | Interval | What happened |
|---|---|---|---|
| 2026-05-11 Progress note 04 (C-CDA) | Methotrexate safety: blood count, liver tests and creatinine | Before starting; every two to four weeks for the first three months; then every eight to twelve weeks | A deviation: the blood count, liver tests and creatinine due two to four weeks after methotrexate began were not done, because no laboratory order was placed for the long gap between visits. No harm resulted: today hemoglobin 13.1 g/dL, white cells 9.8 (raised by prednisone), lymphocytes 1.2, platelets 262, ALT 31, AST 28, alkaline phosphatase 96 U/L, albumin 4.1 g/dL, creatinine 0.92 mg/dL and eGFR 75 are normal. Corrective action: standing orders every four weeks until twelve weeks and then every eight to twelve weeks, at a laboratory near home or on tour, with a reminder to her and to the clinic |
| Visit | Type | Item | Status | Detail |
|---|---|---|---|---|
| 2026-02-23 Progress note 02 (C-CDA) | Laboratory | Exclusion of other granulomatous causes | Ordered | Acid-fast and fungal stains negative; mycobacterial and fungal cultures pending, final in six to eight weeks; interferon-gamma release assay and HIV negative from the first visit |
| 2026-02-23 Progress note 02 (C-CDA) | Examination | Holter monitoring | Ordered | Tomorrow |
| 2026-02-23 Progress note 02 (C-CDA) | Imaging | Echocardiogram | Ordered | This week |
| 2026-02-23 Progress note 02 (C-CDA) | Imaging | Cardiac MRI with late gadolinium enhancement | Ordered | Within two weeks |
| 2026-02-23 Progress note 02 (C-CDA) | Imaging | Cardiac FDG-PET | Ordered | Within two weeks, after a 72-hour high-fat, very-low-carbohydrate diet |
| 2026-02-23 Progress note 02 (C-CDA) | Examination | Eye examination | Ordered | Ophthalmology appointment next week |
| 2026-02-23 Progress note 02 (C-CDA) | Laboratory | Hepatitis B and C screening | Ordered | Hepatitis B surface antigen, core antibody and surface antibody, and hepatitis C antibody drawn today |
| 2026-03-09 Progress note 03 (C-CDA) | Laboratory | Exclusion of other granulomatous causes | Ordered | Cultures no growth at three weeks; final at six to eight weeks |
| 2026-03-09 Progress note 03 (C-CDA) | Imaging | Bone density (DXA) and FRAX | Ordered | Booked for next week |
| 2026-03-09 Progress note 03 (C-CDA) | Referral | Cardiology and electrophysiology | Referred | Seen with Dr. Asante-Miller today; electrophysiology study booked for next week |
| 2026-10-05 Progress note 07 (C-CDA) | Prevention | Breast cancer screening | Ordered | Mammogram every two years from 40; last one three years ago; ordered today |
| Claim | Statement | Certainty |
|---|---|---|
| CLM-0011 | The cause of her death is recorded differently: a heart seizure (The New York Times), heart failure (PBS), a heart attack (Biography.com), heart complications at home (New Orleans Historical), and death in recovery after surgery for a bowel obstruction, which one account attributes to sarcoidosis (Wikipedia, TheWrap). | disputed |
| CLM-0012 | That her heart disease, and the heart trouble that recurred until her death, was cardiac sarcoidosis is a retrospective interpretation. It rests on the private account of her doctors in 1964 reported by her biographer; the public diagnoses were heart strain, exhaustion and heart trouble. | possible |
| Claim | Grade | Statement |
|---|---|---|
| CLM-0011 | R | The cause of her death is recorded differently: a heart seizure (The New York Times), heart failure (PBS), a heart attack (Biography.com), heart complications at home (New Orleans Historical), and death in recovery after surgery for a bowel obstruction, which one account attributes to sarcoidosis (Wikipedia, TheWrap). |
None.
Every note in the record, with its type. All clinical content is synthetic.
| Date | Result | Value | Flag |
|---|---|---|---|
| 2026-02-09 | Lymphocyte count | 0.9 10*3/uL (low) | Low |
| 2026-02-09 | Creatinine | 1.08 mg/dL (high) | High |
| 2026-02-09 | Glucose | 104 mg/dL (high) | High |
| 2026-02-09 | Calcium | 10.8 mg/dL (high) | High |
| 2026-02-09 | Alkaline phosphatase | 128 U/L (high) | High |
| 2026-02-09 | Hemoglobin A1c | 5.9% (high) | High |
| 2026-02-09 | 25-hydroxyvitamin D | 22 ng/mL (low) | Low |
| 2026-02-09 | 1,25-dihydroxyvitamin D | 84 pg/mL (high) | High |
| 2026-02-09 | NT-proBNP | 210 pg/mL (high) | High |
| 2026-02-23 | FVC percent predicted | 74% (low) | Low |
| 2026-02-23 | FEV1 percent predicted | 76% (low) | Low |
| 2026-02-23 | DLCO percent predicted | 62% (low) | Low |
| 2026-02-23 | Calcium | 10.7 mg/dL (high) | High |
| 2026-03-09 | Lymphocyte count | 0.9 10*3/uL (low) | Low |
| 2026-03-09 | Glucose | 101 mg/dL (high) | High |
| 2026-03-09 | Calcium | 10.6 mg/dL (high) | High |
| 2026-03-09 | Alkaline phosphatase | 124 U/L (high) | High |
| 2026-03-09 | NT-proBNP | 240 pg/mL (high) | High |
| 2026-05-11 | Glucose | 118 mg/dL (high) | High |
| 2026-05-11 | Hemoglobin A1c | 6.3% (high) | High |
| 2026-05-11 | 25-hydroxyvitamin D | 24 ng/mL (low) | Low |
| 2026-05-11 | NT-proBNP | 140 pg/mL (high) | High |
| 2026-05-11 | DLCO percent predicted | 70% (low) | Low |
| 2026-08-24 | Glucose | 108 mg/dL (high) | High |
| 2026-08-24 | Hemoglobin A1c | 6.2% (high) | High |
| 2026-08-24 | DLCO percent predicted | 76% (low) | Low |
| 2026-10-05 | Total cholesterol | 204 mg/dL (high) | High |